{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:42:49Z","timestamp":1787002969306,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015524\/1"],"award-info":[{"award-number":["MR\/K015524\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015524\/1"],"award-info":[{"award-number":["MR\/K015524\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015524\/1"],"award-info":[{"award-number":["MR\/K015524\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015524\/1"],"award-info":[{"award-number":["MR\/K015524\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cannabidiol (CBD) has shown promise in treating psychiatric disorders, including cannabis use disorder \u2013 a major public health burden with no approved pharmacotherapies. However, the mechanisms through which CBD acts are poorly understood. One potential mechanism of CBD is increasing levels of anandamide, which has been implicated in psychiatric disorders including depression and cannabis use disorder. However, there is a lack of placebo-controlled human trials investigating this in psychiatric disorders. We therefore assessed whether CBD affects plasma anandamide levels compared to placebo, within a randomised clinical trial of CBD for the treatment of cannabis use disorder. Individuals meeting criteria for cannabis use disorder and attempting cannabis cessation were randomised to 28-day administration with placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200923), 400\u2009mg CBD\/day (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924) or 800\u2009mg CBD\/day (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200923). We estimated the effects of each CBD dose compared to placebo on anandamide levels from baseline to day 28. Analyses were conducted both unadjusted and adjusted for cannabis use during the trial to account for effects of cannabis on the endocannabinoid system. We also investigated whether changes in plasma anandamide levels were associated with clinical outcomes relevant for cannabis use disorder (cannabis use, withdrawal, anxiety, depression). There was an effect of 800\u2009mg CBD compared to placebo on anandamide levels from baseline to day 28 after adjusting for cannabis use. Pairwise comparisons indicated that anandamide levels unexpectedly reduced from baseline to day 28 in the placebo group (\u22120.048, 95% CI [\u22120.089, \u22120.007]), but did not change in the 800\u2009mg CBD group (0.005, 95% CI [\u22120.036, 0.047]). There was no evidence for an effect of 400\u2009mg CBD compared to placebo. Changes in anandamide levels were not associated with clinical outcomes. In conclusion, this study found preliminary evidence that 28-day treatment with CBD modulates anandamide levels in individuals with cannabis use disorder at doses of 800\u2009mg\/day but not 400\u2009mg\/day compared to placebo.\n                  <\/jats:p>","DOI":"10.1038\/s41398-023-02410-9","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:02:11Z","timestamp":1682035331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-4957","authenticated-orcid":false,"given":"Daniel Ying-Heng","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandni","family":"Hindocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Baio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mofeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Valerie","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-507X","authenticated-orcid":false,"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2410_CR1","first-page":"495","volume":"109","author":"F Grotenhermen","year":"2012","unstructured":"Grotenhermen F, M\u00fcller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch \u00c4rztebl Int. 2012;109:495\u2013501.","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2410_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12210-020-00966-y","volume":"32","author":"F Piscitelli","year":"2021","unstructured":"Piscitelli F, Di Marzo V. Cannabinoids: a class of unique natural products with unique pharmacology. Rendiconti Lincei Sci Fis E Nat. 2021;32:5\u201315.","journal-title":"Rendiconti Lincei Sci Fis E Nat"},{"key":"2410_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/jcb.10291","volume":"88","author":"RB Zurier","year":"2003","unstructured":"Zurier RB. Prospects for cannabinoids as anti\u2010inflammatory agents. J Cell Biochem. 2003;88:462\u20136.","journal-title":"J Cell Biochem"},{"key":"2410_CR4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020;45:1799\u2013806.","journal-title":"Neuropsychopharmacology"},{"key":"2410_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1474-4422(20)30060-0","volume":"19","author":"A Lamb","year":"2020","unstructured":"Lamb A, Dawoud D, Dent R, Elliott N, Adler AI. Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes. Lancet Neurol. 2020;19:290\u20131.","journal-title":"Lancet Neurol"},{"key":"2410_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN, De Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"2410_CR7","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl). 2018;235:1923\u201332.","journal-title":"Psychopharmacology (Berl)"},{"key":"2410_CR8","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"F Leweke","year":"2012","unstructured":"Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94\u2013e94.","journal-title":"Transl Psychiatry"},{"key":"2410_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175:225\u201331.","journal-title":"Am J Psychiatry"},{"key":"2410_CR10","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2018: Trends and Developments. 2018. https:\/\/www.emcdda.europa.eu\/publications\/edr\/trends-developments\/2018_en."},{"key":"2410_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","volume":"156","author":"LB Resstel","year":"2009","unstructured":"Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corr\u00eaa FM, Guimar\u00e3es FS. 5\u2010HT1A receptors are involved in the cannabidiol\u2010induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharm. 2009;156:181\u20138.","journal-title":"Br J Pharm"},{"key":"2410_CR12","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/npp.2010.58","volume":"35","author":"CJ Morgan","year":"2010","unstructured":"Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of \u03949-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35:1879\u201385.","journal-title":"Neuropsychopharmacology"},{"key":"2410_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JAS Crippa","year":"2011","unstructured":"Crippa JAS, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacology (Oxf). 2011;25:121\u201330.","journal-title":"J Psychopharmacology (Oxf)"},{"key":"2410_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban ND, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7:865\u201374.","journal-title":"Lancet Psychiatry"},{"key":"2410_CR15","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/add.15253","volume":"116","author":"TP Freeman","year":"2021","unstructured":"Freeman TP, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M, et al. Changes in delta\u20109\u2010tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta\u2010analysis. Addiction. 2021;116:1000\u201310.","journal-title":"Addiction"},{"key":"2410_CR16","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","volume":"44","author":"CM Pretzsch","year":"2019","unstructured":"Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019;44:1398\u2013405.","journal-title":"Neuropsychopharmacology"},{"key":"2410_CR17","doi-asserted-by":"publisher","first-page":"e00682","DOI":"10.1002\/prp2.682","volume":"8","author":"DL de Almeida","year":"2020","unstructured":"de Almeida DL, Devi LA. Diversity of molecular targets and signaling pathways for CBD. Pharm Res Perspect. 2020;8:e00682.","journal-title":"Pharm Res Perspect"},{"key":"2410_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fnbeh.2012.00009","volume":"6","author":"N Battista","year":"2012","unstructured":"Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front Behav Neurosci. 2012;6:9.","journal-title":"Front Behav Neurosci"},{"key":"2410_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0090-6980(00)00051-4","volume":"61","author":"CJ Hillard","year":"2000","unstructured":"Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat. 2000;61:3\u201318.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2410_CR20","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1073\/pnas.1514996112","volume":"112","author":"J Fuss","year":"2015","unstructured":"Fuss J, Steinle J, Bindila L, Auer MK, Kirchherr H, Lutz B, et al. A runner\u2019s high depends on cannabinoid receptors in mice. Proc Natl Acad Sci. 2015;112:13105\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"2410_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nm803","volume":"9","author":"S Kathuria","year":"2003","unstructured":"Kathuria S, Gaetani S, Fegley D, Vali\u00f1o F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9:76\u201381.","journal-title":"Nat Med"},{"key":"2410_CR22","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1073\/pnas.1600013113","volume":"113","author":"DG Gee","year":"2016","unstructured":"Gee DG, Fetcho RN, Jing D, Li A, Glatt CE, Drysdale AT, et al. Individual differences in frontolimbic circuitry and anxiety emerge with adolescent changes in endocannabinoid signaling across species. Proc Natl Acad Sci. 2016;113:4500\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"2410_CR23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","volume":"34","author":"MN Hill","year":"2009","unstructured":"Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology. 2009;34:1257\u201362.","journal-title":"Psychoneuroendocrinology"},{"key":"2410_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrn4004","volume":"16","author":"LH Parsons","year":"2015","unstructured":"Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci. 2015;16:579\u201394.","journal-title":"Nat Rev Neurosci"},{"key":"2410_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrn.2016.28","volume":"17","author":"HV Curran","year":"2016","unstructured":"Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17:293\u2013306.","journal-title":"Nat Rev Neurosci"},{"key":"2410_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1192\/bjp.bp.112.121178","volume":"202","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Page E, Schaefer C, Chatten K, Manocha A, Gulati S, et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry. 2013;202:381\u20132.","journal-title":"Br J Psychiatry"},{"key":"2410_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/mp.2011.82","volume":"17","author":"J Hirvonen","year":"2012","unstructured":"Hirvonen J, Goodwin R, Li C-T, Terry G, Zoghbi S, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17:642\u20139.","journal-title":"Mol Psychiatry"},{"key":"2410_CR28","doi-asserted-by":"publisher","first-page":"e13061","DOI":"10.1111\/adb.13061","volume":"26","author":"TR Spindle","year":"2021","unstructured":"Spindle TR, Kuwabara H, Eversole A, Nandi A, Vandrey R, Antoine DG, et al. Brain imaging of cannabinoid type I (CB1) receptors in women with cannabis use disorder and male and female healthy controls. Addict Biol. 2021;26:e13061.","journal-title":"Addict Biol"},{"key":"2410_CR29","first-page":"60","volume":"1","author":"DC D\u2019Souza","year":"2016","unstructured":"D\u2019Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, et al. Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1:60\u20137.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2410_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","volume":"6","author":"DC D\u2019Souza","year":"2019","unstructured":"D\u2019Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6:35\u201345.","journal-title":"Lancet Psychiatry"},{"key":"2410_CR31","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1124\/dmd.109.026930","volume":"37","author":"S Takeda","year":"2009","unstructured":"Takeda S, Usami N, Yamamoto I, Watanabe K. Cannabidiol-2\u2032, 6\u2032-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor. Drug Metab Dispos. 2009;37:1733\u20137.","journal-title":"Drug Metab Dispos"},{"key":"2410_CR32","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015;290:8711\u201321.","journal-title":"J Biol Chem"},{"key":"2410_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bcp.2018.08.046","volume":"157","author":"G Navarro","year":"2018","unstructured":"Navarro G, Reyes-Resina I, Rivas-Santisteban R, de Medina VS, Morales P, Casano S, et al. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. Biochem Pharm. 2018;157:148\u201358.","journal-title":"Biochem Pharm"},{"key":"2410_CR34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1017\/S1461145712001502","volume":"16","author":"AC Campos","year":"2013","unstructured":"Campos AC, Ortega Z, Palazuelos J, Foga\u00e7a MV, Aguiar DC, D\u00edaz-Alonso J, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol. 2013;16:1407\u201319.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2410_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamapsychiatry.2019.4157","volume":"77","author":"YL Hurd","year":"2020","unstructured":"Hurd YL. Leading the next CBD wave\u2014safety and efficacy. JAMA Psychiatry. 2020;77:341\u20132.","journal-title":"JAMA Psychiatry"},{"key":"2410_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drugalcdep.2011.11.007","volume":"123","author":"DA Gorelick","year":"2012","unstructured":"Gorelick DA, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, et al. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend. 2012;123:141\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"2410_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drugalcdep.2012.07.012","volume":"128","author":"D Kotz","year":"2013","unstructured":"Kotz D, Brown J, West R. Predictive validity of the Motivation To Stop Scale (MTSS): a single-item measure of motivation to stop smoking. Drug Alcohol Depend. 2013;128:15\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"2410_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1049731509347850","volume":"20","author":"BW Lundahl","year":"2010","unstructured":"Lundahl BW, Kunz C, Brownell C, Tollefson D, Burke BL. A meta-analysis of motivational interviewing: Twenty-five years of empirical studies. Res Soc Work Pr. 2010;20:137\u201360.","journal-title":"Res Soc Work Pr"},{"key":"2410_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000515667","volume":"27","author":"C Calomarde-G\u00f3mez","year":"2021","unstructured":"Calomarde-G\u00f3mez C, Jimenez-Fernandez B, Balcells-Oliver\u00f3 M, Gual A, L\u00f3pez-Pelayo H. Motivational interviewing for cannabis use disorders: a systematic review and meta-analysis. Eur Addict Res. 2021;27:413\u201327.","journal-title":"Eur Addict Res"},{"key":"2410_CR40","unstructured":"Department of Health. Drug misuse and dependence: UK guidelines on clinical management. 2007. https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20130123164248mp_\/http:\/\/www.nta.nhs.uk\/%2fuploads%2fclinical_guidelines_2007.pdf."},{"key":"2410_CR41","doi-asserted-by":"crossref","unstructured":"Sobell LC, Sobell MB. Timeline follow-back. In: Litten RZ, Allen JP, editors. Measuring alcohol consumption Ch. 3. Berlin: Springer; 1992.","DOI":"10.1007\/978-1-4612-0357-5_3"},{"key":"2410_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drugalcdep.2011.06.003","volume":"119","author":"DJ Allsop","year":"2011","unstructured":"Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;119:123\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"2410_CR43","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893\u20137.","journal-title":"J Consult Clin Psychol"},{"key":"2410_CR44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561\u201371.","journal-title":"Arch Gen Psychiatry"},{"key":"2410_CR45","unstructured":"Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics. Boston, MA: Pearson; 2007."},{"key":"2410_CR46","unstructured":"Byrne BM. Structural equation modeling with AMOS: basic concepts, applications, and programming. Multivariate applications series. New York: Taylor Francis Group; 2010."},{"key":"2410_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JE, Guimar\u00e3es FS, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharm. 2017;8:259.","journal-title":"Front Pharm"},{"key":"2410_CR48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrn1247","volume":"4","author":"D Piomelli","year":"2003","unstructured":"Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873\u201384.","journal-title":"Nat Rev Neurosci"},{"key":"2410_CR49","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1093\/humrep\/dep065","volume":"24","author":"MR El-Talatini","year":"2009","unstructured":"El-Talatini MR, Taylor AH, Konje JC. Fluctuation in anandamide levels from ovulation to early pregnancy in in-vitro fertilization-embryo transfer women, and its hormonal regulation. Hum Reprod. 2009;24:1989\u201398.","journal-title":"Hum Reprod"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02410-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02410-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02410-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:03:07Z","timestamp":1682035387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02410-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2410"],"URL":"https:\/\/doi.org\/10.1038\/s41398-023-02410-9","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CH is employed by GW pharmaceuticals. Her contribution to this work occurred before moving from UCL to this position. All other authors have no potential conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}